美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Kurv Yield Premium Strategy Tesla (TSLA) ETF

19.57

-0.2200-1.11%

成交量：2.48万

成交额：48.86万

市值：2,172.27万

市盈率：- -

高：19.89

开：19.89

低：19.54

收：19.79

数据加载中...

总览公司新闻公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻

阿斯利康2025H1：营收280亿美元！Enhertu大卖22.89亿美元，TSLP单抗增长73%

和铂医药公布2024年度业绩

【华海药业：下属子公司获HB0056注射液临床试验许可】金融界2月21日消息，近日，华海药业下属子公司上海华奥泰生物药业股份有限公司和华博生物医药技术（上海）有限公司收到国家药品监督管理局核准签发的HB0056注射液的《药物临床试验批准通知书》。该药物适应症为哮喘，剂型为注射剂。2024年10月，子公司获新西兰相关部门批准开展I期临床试验；2025年1月，获美国食品药品监督管理局批准在美国开展临床试验；2024年12月4日向国家药监局提交临床试验申请并于近日获批。公司在HB0056项目上已合计投入研发费用约6,367万元。HB0056是双特异性抗体，能靶向TSLP和IL-11。2022年国内哮喘药物市场规模达38亿美元。但医药产品研发存风险。

【和铂医药-B(02142.HK)：针对治疗慢性阻塞性肺病的HBM9378/SKB378获批NMPA的IND许可】和铂医药-B(02142.HK)发布公告，集团针对胸腺基质淋巴细胞生成素(TSLP)的全人源单克隆抗体HBM9378/SKB378(亦称为WIN378)已获得中国国家药品监督管理局(NMPA)药品审评中心的新药研究申请(IND)批件，以开展治疗慢性阻塞性肺病(COPD)的临床试验。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/TSLP"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TSLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TSLP\",,,,,undefined,":{"symbol":"TSLP","market":"US","secType":"STK","nameCN":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","latestPrice":19.57,"timestamp":1753902601693,"preClose":19.79,"halted":0,"volume":24839,"delay":0,"floatShares":1110000,"shares":1110000,"eps":0,"marketStatus":"交易中","change":-0.22,"latestTime":"07-30 15:11:16 EDT","open":19.888,"high":19.888,"low":19.54,"amount":488623.692087,"amplitude":0.017585,"askPrice":20.2,"askSize":100,"bidPrice":19.45,"bidSize":6,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1753905600000},"marketStatusCode":2,"adr":0,"exchange":"AMEX","adjPreClose":19.79,"sharesOutstanding":1110000,"nav":19.91,"aum":22100100,"dividendRate":0.432294,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":19.7,"preClose":19.79,"latestTime":"09:13 EDT","volume":9,"amount":179.86001399999998,"timestamp":1753881237602},"postHourTrading":{"tag":"盘后","latestPrice":19.79,"preClose":19.79,"latestTime":"18:05 EDT","volume":11,"amount":217.55,"timestamp":1753826715395},"volumeRatio":0.748836,"impliedVol":0.266,"impliedVolPercentile":0.484},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TSLP\",,,,,undefined,":{"symbol":"TSLP","floatShares":1110000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.748836,"shares":1110000,"dividePrice":8.46,"high":19.888,"amplitude":0.017585,"preClose":19.79,"low":19.54,"week52Low":15.36,"pbRate":"--","week52High":34.2895,"institutionHeld":0,"latestPrice":19.57,"committee":-0.886792,"eps":0,"divideRate":0.432294,"volume":24839,"delay":0,"ttmEps":0,"open":19.888,"prevYearClose":30.27,"prevWeekClose":19.5236,"prevMonthClose":20.31,"prevQuarterClose":20.31,"fiveDayClose":20.44,"twentyDayClose":19.24,"sixtyDayClose":19.9339},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TSLP\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TSLP\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2555388080","title":"阿斯利康2025H1：营收280亿美元！Enhertu大卖22.89亿美元，TSLP单抗增长73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555388080","media":"医药魔方","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555388080?lang=zh_cn&edition=fundamental","pubTime":"2025-07-29 14:48","pubTimestamp":1753771713,"startTime":"0","endTime":"0","summary":"7月29日，阿斯利康公布2025年H1业绩，上半年总营收280.45亿美元，其中产品收入279.63亿美元；研发投入亿美元，同比增长%。若计入第一三共报告的收入，Enhertu上半年销售额为22.89亿美元。其销售额还在起步阶段，在上半年为阿斯利康创收0.14亿美元。Truqap是阿斯利康在肿瘤领域推出的另一支潜力股，上市以来持续发力，上半年畅销3.02亿美元，已接近2024年全年销售额。今年上半年，Beyfortus销售额较同期增长2倍以上，为阿斯利康带来2.38亿美元的收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729145517a6c74492&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729145517a6c74492&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TSLP","AZN"],"gpt_icon":0},{"id":"2523948329","title":"和铂医药公布2024年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2523948329","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523948329?lang=zh_cn&edition=fundamental","pubTime":"2025-03-31 18:13","pubTimestamp":1743415980,"startTime":"0","endTime":"0","summary":"中国上海、美国马萨诸塞州剑桥和荷兰鹿特丹2025年3月31日 /美通社/ -- 和铂医药，一家专注于免疫性疾病及肿瘤领域创新药研发的全球生物医药公司，今日公布其2024年度业绩。同时，和铂医药保持稳健的财务状况，截至 2024 年 12 月 31 日，公司现金及现金等价物约12亿元人民币，为后续发展奠定了坚实的财务基础。公司于2022年2月获得NMPA对HBM9378治疗中重度哮喘的IND批准，随后在中国完成对健康受试者的I期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4653322_ZH53322_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1039938227.USD","LU0942090050.USD","LU0128525929.USD","LU1863844749.USD","BK4006","LU1035777561.USD","LU0868494617.USD","02142","GB00BDT5M118.USD","LU0314106906.USD","BK1583","LU1804176565.USD","LU2065731478.USD","LU1291149836.SGD","BK4011","LU1093756325.SGD","LU2041044095.USD","LU1019632923.USD","IE00B66KJ199.SGD","CRH","LU2265009873.SGD","SD","LU0868494708.USD","LU1506573853.SGD","IE00B19Z4B17.USD","LU0238689110.USD","LU1880398554.USD","LU2298321311.HKD","LU0708994859.HKD","LU0310800379.SGD","BK1574","BK4213","TSLP","LU2092937221.SGD","LU1863844665.USD","LU2360108059.USD","LU0029864427.USD","LU1093756168.USD","CRS","IE0031619046.USD","LU1019634622.SGD","IE00B7SZL793.SGD","LU1880398471.USD","LU1267930573.SGD","LU2463526074.USD","BK1161"],"gpt_icon":1},{"id":"2513043254","title":"【华海药业：下属子公司获HB0056注射液临床试验许可】金融界2月21日消息，近日，华海药业下属子公司上海华奥泰生物药业股份有限公司和华博生物医药技术（上海）有限公司收到国家药品监督管理局核准签发的HB0056注射液的《药物临床试验批准通知书》。该药物适应症为哮喘，剂型为注射剂。2024年10月，子公司获新西兰相关部门批准开展I期临床试验；2025年1月，获美国食品药品监督管理局批准在美国开展临床试验；2024年12月4日向国家药监局提交临床试验申请并于近日获批。公司在HB0056项目上已合计投入研发费用约6,367万元。HB0056是双特异性抗体，能靶向TSLP和IL-11。2022年国内哮喘药物市场规模达38亿美元。但医药产品研发存风险。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513043254","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513043254?lang=zh_cn&edition=fundamental","pubTime":"2025-02-21 17:27","pubTimestamp":1740130054,"startTime":"0","endTime":"0","summary":"金融界2月21日消息，近日，华海药业下属子公司上海华奥泰生物药业股份有限公司和华博生物医药技术（上海）有限公司收到国家药品监督管理局核准签发的HB0056注射液的《药物临床试验批准通知书》。该药物适应症为哮喘，剂型为注射剂。2024年10月，子公司获新西兰相关部门批准开展I期临床试验；2025年1月，获美国食品药品监督管理局批准在美国开展临床试验；2024年12月4日向国家药监局提交临床试验申请并于近日获批。公司在HB0056项目上已合计投入研发费用约6,367万元。HB0056是双特异性抗体，能靶向TSLP和IL-11。2022年国内哮喘药物市场规模达38亿美元。但医药产品研发存风险。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/21172748309954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","BK0188","BK1583","BK1141","BK1515","BK0201","03347","TSLP","161726","BK0185","399441","BK0012","159938","BK0028","BK1576","BK0070","600521","BK1161","BK1574","09939","688606"],"gpt_icon":0},{"id":"2509668428","title":"【和铂医药-B(02142.HK)：针对治疗慢性阻塞性肺病的HBM9378/SKB378获批NMPA的IND许可】和铂医药-B(02142.HK)发布公告，集团针对胸腺基质淋巴细胞生成素(TSLP)的全人源单克隆抗体HBM9378/SKB378(亦称为WIN378)已获得中国国家药品监督管理局(NMPA)药品审评中心的新药研究申请(IND)批件，以开展治疗慢性阻塞性肺病(COPD)的临床试验。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509668428","media":"金融界","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509668428?lang=zh_cn&edition=fundamental","pubTime":"2025-02-05 12:44","pubTimestamp":1738730657,"startTime":"0","endTime":"0","summary":"和铂医药-B(02142.HK)发布公告，集团针对胸腺基质淋巴细胞生成素(TSLP)的全人源单克隆抗体HBM9378/SKB378(亦称为WIN378)已获得中国国家药品监督管理局(NMPA)药品审评中心的新药研究申请(IND)批件，以开展治疗慢性阻塞性肺病(COPD)的临床试验。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/05124447953908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","BK1576","BK1583","BK1161","BK1574","03347","02142","TSLP"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TSLP\",params:#limit:5,,,undefined,":[{"date":"2025-07-02","symbol":"TSLP","amount":0.45,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-02","defaultRemindTime":1751463000000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-03","payableDate":"2025-07-02","currency":"USD","dateTimestamp":1751428800000,"payDate":"2025-07-03"},{"date":"2025-06-04","symbol":"TSLP","amount":0.5,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-04","defaultRemindTime":1749043800000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-05","payableDate":"2025-06-04","currency":"USD","dateTimestamp":1749009600000,"payDate":"2025-06-05"},{"date":"2025-05-07","symbol":"TSLP","amount":0.55,"announcedDate":"2025-05-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-07","defaultRemindTime":1746624600000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-08","payableDate":"2025-05-07","currency":"USD","dateTimestamp":1746590400000,"payDate":"2025-05-08"},{"date":"2025-04-02","symbol":"TSLP","amount":0.55,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-02","defaultRemindTime":1743600600000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-03","payableDate":"2025-04-02","currency":"USD","dateTimestamp":1743566400000,"payDate":"2025-04-03"},{"date":"2025-03-05","symbol":"TSLP","amount":0.7,"announcedDate":"2025-03-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-05","defaultRemindTime":1741185000000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-06","payableDate":"2025-03-05","currency":"USD","dateTimestamp":1741150800000,"payDate":"2025-03-06"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TSLP\",market:\"US\",,,undefined,":[{"executeDate":"2023-11-22","recordDate":"2023-11-24","paymentDate":"2023-11-27","value":0.5775,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-22","value":0.6664,"currency":"USD"},{"executeDate":"2024-01-24","recordDate":"2024-01-25","paymentDate":"2024-01-26","value":0.5555,"currency":"USD"},{"executeDate":"2024-02-21","recordDate":"2024-02-22","paymentDate":"2024-02-23","value":0.313,"currency":"USD"},{"executeDate":"2024-03-20","recordDate":"2024-03-21","paymentDate":"2024-03-22","value":0.5189,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TSLP\",market:\"US\",delay:false,,,undefined,":{}}}